Developer docs
API playgroundTry for free, no card

Search company profiles

Sampling Human

Full company profile

uuid00027jm

Namestring
Sampling Human
Legal namestring
Sampling Human, Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Sampling Human is a private biotechnology company founded in 2022 that builds production systems for generating cellular-resolution data from clinical samples. Headquartered in Berkeley, California with a technical operations office in Pilsen, Czech Republic, the company operates with a headcount between 11 and 50 employees and serves diagnostic, health, and research organizations. Its positioning is built on converting variable clinical inputs and application-specific biology into standardized, structured cellular data at production scale, with three named vertical focuses: longevity (N-of-1 health intelligence), prenatal (non-invasive fetal genetics and placental function), and oncology (mechanistic disease monitoring).

The platform architecture is composed of five integrated components: proprietary Encoding Chemistry (multidimensional barcoding that overcomes existing barcoding limits and scales per sample), Selective Singulation (focused sequencing on relevant cells and signals), AI Decoding Models (a foundation model that maps barcode space into sample-level representations and shifts assay complexity to computation), Physical Tokenization (automated quality-controlled annotations across novel patient-specific cellular states), and Production Layer Integration (an end-to-end workflow designed for automated molecular lab infrastructure). Commercially, the company delivers the Sequencing Platform and Cloud Service under subscription, supported by physical SamplingOne™ Kits for sample collection and Technical Services for sample processing, with quote-based pricing, 30-day quotation validity, and 30-day payment terms.

The company has raised approximately $2 million in seed funding (April 2022) led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. It is co-founded by Daniel Georgiev (CEO), Hynek Kasl (Head of Engineering), and Martin Cienciala (Head of Innovation). The go-to-market is enterprise-focused through direct outreach to diagnostic, health, and research organizations, supplemented by digital channels (LinkedIn, Twitter/X, email newsletter, website content). No named customers, revenue figures, follow-on financing events, or commercialization milestones have been disclosed in the available data.

Short descriptiontext

Sampling Human builds production systems for generating cellular-resolution data from clinical samples, serving diagnostic, health, and research organizations with a proprietary sequencing platform, cloud service, and sample collection kits.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cellular-resolution sequencing, single-cell genomics platform, clinical diagnostics data, AI decoding models, liquid biopsy analysis
Industry3 codes
1Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
CodeHLAAALAOPrimaryYes
2Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
CodeHLAHAAANPrimaryNo
3AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
CodeHLAAAIAEPrimaryNo
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Genomics Sequencing Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Subscription
TypeSubscription Recurring
Description

Customers subscribe to access the Sequencing Platform and Cloud Service. Access is granted for internal business purposes during the Services Term with non-exclusive, non-transferable rights.

samplinghuman.com
2SamplingOne™ Kit Sales
TypeHardware Sales
Description

Sale of physical kit components for sample collection and processing. Kits are shipped to customers with warranty coverage until the expiration date on the package.

samplinghuman.com
3Technical Services
TypeProfessional Services
Description

Technical or professional services performed by Sampling Human as described in applicable Orders, including processing Customer Samples.

samplinghuman.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom quotation-based pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Pricing based on written quotation provided to customer. Quotation valid for 30 days unless stated otherwise.

samplinghuman.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Sampling Human builds production systems for generating cellular-resolution data from clinical samples, combining a Sequencing Platform, a Cloud Service, and a physical SamplingOne™ Kit. The platform applies proprietary multidimensional encoding chemistry and AI decoding models to convert clinical samples into standardized, structured cellular data for diagnostics, health products, and AI models. Revenue is generated through platform subscriptions, kit sales, and technical services via direct enterprise sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Platform generates cellular-resolution data at clinical scale
Product overview1 text field

Sampling Human offers a unified platform for generating cellular-resolution data from clinical samples. The core offering consists of the Sequencing Platform (software and analysis system), Cloud Service (for data upload and management), and SamplingOne™ Kit (physical sample collection component), supported by Technical Services. The platform is built on proprietary Encoding Chemistry and Decoding Models that work together to transform complex clinical samples into standardized, structured cellular data at production scale for diagnostics, health products, and AI models.

Product and service4 records
1Sequencing Platform
CategoryCore Product
Description

Sampling Human's platform application including all related software, hardware, products, processes, algorithms, user interfaces, know-how, techniques, designs, and other technical material for generating cellular-resolution data from clinical samples. Made available to customers pursuant to an Order.

2Cloud Service
CategoryCore Product
Description

The cloud-based platform through which users can upload their sequences for analysis by Sampling Human, including the content of the platform, algorithms, and machine learning capabilities. Accessed via the hosted website.

3SamplingOne™ Kit
CategoryProduct
Description

A physical kit for sample collection designed for stable sample collection and integration with the Sequencing Platform for automated molecular lab infrastructure. Kits are shipped to customers with warranty coverage until the expiration date on the package.

4Technical Services
CategoryService
Description

Technical or professional services performed by Sampling Human as described in an applicable Order, including processing Customer Samples and generating Results.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics is the dominant single-cell sequencing platform provider (Chromium, Visium, Xenium). It is the closest direct competitor to Sampling Human's cellular-resolution sequencing platform, with overlapping applications in oncology, immunology, and translational research.

TypeDirect peer
Description

Mission Bio provides single-cell multi-omics platforms (Tapestri) focused on oncology and clinical applications such as measurable residual disease. Like Sampling Human, it targets clinical and translational research customers with single-cell resolution for patient-level biology.

TypeDirect peer
Description

Parse Biosciences offers scalable single-cell sequencing solutions (Evercode) used in research and translational settings. It competes with Sampling Human in providing high-throughput, lower-touch single-cell workflows for clinical and research customers.

TypeDirect peer
Description

Fluent Biosciences develops single-cell sequencing technologies with a focus on simplified, scalable workflows. Its product positioning around cost-effective, automation-friendly single-cell prep directly overlaps with Sampling Human's production-scale platform.

TypeBroad incumbent
Description

BD's Rhapsody single-cell platform and broader life-sciences instrumentation portfolio make it a broad incumbent offering overlapping cellular-resolution capabilities. BD competes with Sampling Human across research and clinical research customers and benefits from an entrenched installed base.

TypeBroad incumbent
Description

Illumina is the dominant sequencing platform provider (NovaSeq, NextSeq) whose instruments underlie most single-cell workflows, including Sampling Human's. While not a direct single-cell competitor, Illumina's technology and reagent ecosystem set the performance and cost benchmark for any new entrant.

TypeDirect peer
Description

Akoya Biosciences provides spatial biology and single-cell analysis platforms (CODEX, Phenoptics) used in immuno-oncology and translational research. It overlaps with Sampling Human's cellular-resolution value proposition, particularly for oncology and immune profiling applications.

TypeEmerging player
Description

Element Biosciences is an emerging sequencing platform company (AVITI) competing with incumbents on cost and flexibility. While not a single-cell pure play, its lower-cost benchtop sequencing instrument could be an enabling or competing technology for Sampling Human-style workflows.

TypeBroad incumbent
Description

Bio-Rad offers ddSEQ single-cell sequencing solutions and a broad life-science research portfolio. As a broad incumbent, it competes with Sampling Human across research customers and benefits from established distribution and reagent pull-through.

TypeEmerging player
Description

Singular Genomics develops benchtop sequencers (G4) aimed at flexible, lower-cost sequencing for research and clinical applications. It is an emerging infrastructure competitor whose platform choices affect how customers approach single-cell and cellular-resolution workflows.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sampling Human

Genomics Sequencing Platformsamplinghuman.com

Sampling Human builds production systems for generating cellular-resolution data from clinical samples, serving diagnostic, health, and research organizations with a proprietary sequencing platform, cloud service, and sample collection kits.

What Sampling Human does

Sampling Human is a private biotechnology company founded in 2022 that builds production systems for generating cellular-resolution data from clinical samples. Headquartered in Berkeley, California with a technical operations office in Pilsen, Czech Republic, the company operates with a headcount between 11 and 50 employees and serves diagnostic, health, and research organizations. Its positioning is built on converting variable clinical inputs and application-specific biology into standardized, structured cellular data at production scale, with three named vertical focuses: longevity (N-of-1 health intelligence), prenatal (non-invasive fetal genetics and placental function), and oncology (mechanistic disease monitoring).

The platform architecture is composed of five integrated components: proprietary Encoding Chemistry (multidimensional barcoding that overcomes existing barcoding limits and scales per sample), Selective Singulation (focused sequencing on relevant cells and signals), AI Decoding Models (a foundation model that maps barcode space into sample-level representations and shifts assay complexity to computation), Physical Tokenization (automated quality-controlled annotations across novel patient-specific cellular states), and Production Layer Integration (an end-to-end workflow designed for automated molecular lab infrastructure). Commercially, the company delivers the Sequencing Platform and Cloud Service under subscription, supported by physical SamplingOne™ Kits for sample collection and Technical Services for sample processing, with quote-based pricing, 30-day quotation validity, and 30-day payment terms.

The company has raised approximately $2 million in seed funding (April 2022) led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. It is co-founded by Daniel Georgiev (CEO), Hynek Kasl (Head of Engineering), and Martin Cienciala (Head of Innovation). The go-to-market is enterprise-focused through direct outreach to diagnostic, health, and research organizations, supplemented by digital channels (LinkedIn, Twitter/X, email newsletter, website content). No named customers, revenue figures, follow-on financing events, or commercialization milestones have been disclosed in the available data.

Sampling Human firmographics

Firmographics
Name
Sampling Human
Legal name
Sampling Human, Inc.
Website
https://samplinghuman.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Sampling Human builds production systems for generating cellular-resolution data from clinical samples, serving diagnostic, health, and research organizations with a proprietary sequencing platform, cloud service, and sample collection kits.
Ownership category
akta.pro rank

Sampling Human industry classification

Industry
Product category
Genomics Sequencing Platform
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro primary industry
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
akta.pro secondary industries
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

  • Cellular-resolution sequencing
  • Single-cell genomics platform
  • Clinical diagnostics data
  • AI decoding models
  • Liquid biopsy analysis

Where Sampling Human is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sampling Human business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Subscription: Customers subscribe to access the Sequencing Platform and Cloud Service. Access is granted for internal business purposes during the Services Term with non-exclusive, non-transferable rights.
  2. SamplingOne™ Kit Sales: Sale of physical kit components for sample collection and processing. Kits are shipped to customers with warranty coverage until the expiration date on the package.
  3. Technical Services: Technical or professional services performed by Sampling Human as described in applicable Orders, including processing Customer Samples.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCustom quotation-based pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Sampling Human product offering

Product offering

Core offering

Sampling Human builds production systems for generating cellular-resolution data from clinical samples, combining a Sequencing Platform, a Cloud Service, and a physical SamplingOne™ Kit. The platform applies proprietary multidimensional encoding chemistry and AI decoding models to convert clinical samples into standardized, structured cellular data for diagnostics, health products, and AI models. Revenue is generated through platform subscriptions, kit sales, and technical services via direct enterprise sales.

Product overview

Sampling Human offers a unified platform for generating cellular-resolution data from clinical samples. The core offering consists of the Sequencing Platform (software and analysis system), Cloud Service (for data upload and management), and SamplingOne™ Kit (physical sample collection component), supported by Technical Services. The platform is built on proprietary Encoding Chemistry and Decoding Models that work together to transform complex clinical samples into standardized, structured cellular data at production scale for diagnostics, health products, and AI models.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sequencing Platform Sampling Human's platform application including all related software, hardware, products, processes, algorithms, user interfaces, know-how, techniques, designs, and other technical material for generating cellular-resolution data from clinical samples. Made available to customers pursuant to an Order.
  • Cloud Service The cloud-based platform through which users can upload their sequences for analysis by Sampling Human, including the content of the platform, algorithms, and machine learning capabilities. Accessed via the hosted website.
  • SamplingOne™ Kit A physical kit for sample collection designed for stable sample collection and integration with the Sequencing Platform for automated molecular lab infrastructure. Kits are shipped to customers with warranty coverage until the expiration date on the package.
  • Technical Services Technical or professional services performed by Sampling Human as described in an applicable Order, including processing Customer Samples and generating Results.

Quantifiable outcome

  • Platform generates cellular-resolution data at clinical scale

Companies that use Sampling Human

Customer profile

Segments3 records

Ideal customer profiles3 records

Sampling Human technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Sampling Human partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sampling Human competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics is the dominant single-cell sequencing platform provider (Chromium, Visium, Xenium). It is the closest direct competitor to Sampling Human's cellular-resolution sequencing platform, with overlapping applications in oncology, immunology, and translational research.
  • Mission Bio: Mission Bio provides single-cell multi-omics platforms (Tapestri) focused on oncology and clinical applications such as measurable residual disease. Like Sampling Human, it targets clinical and translational research customers with single-cell resolution for patient-level biology.
  • Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing solutions (Evercode) used in research and translational settings. It competes with Sampling Human in providing high-throughput, lower-touch single-cell workflows for clinical and research customers.
  • Fluent Biosciences: Fluent Biosciences develops single-cell sequencing technologies with a focus on simplified, scalable workflows. Its product positioning around cost-effective, automation-friendly single-cell prep directly overlaps with Sampling Human's production-scale platform.
  • Akoya Biosciences: Akoya Biosciences provides spatial biology and single-cell analysis platforms (CODEX, Phenoptics) used in immuno-oncology and translational research. It overlaps with Sampling Human's cellular-resolution value proposition, particularly for oncology and immune profiling applications.

Broad incumbents

  • Becton, Dickinson and Company (BD) — BD Biosciences: BD's Rhapsody single-cell platform and broader life-sciences instrumentation portfolio make it a broad incumbent offering overlapping cellular-resolution capabilities. BD competes with Sampling Human across research and clinical research customers and benefits from an entrenched installed base.
  • Illumina: Illumina is the dominant sequencing platform provider (NovaSeq, NextSeq) whose instruments underlie most single-cell workflows, including Sampling Human's. While not a direct single-cell competitor, Illumina's technology and reagent ecosystem set the performance and cost benchmark for any new entrant.
  • Bio-Rad Laboratories: Bio-Rad offers ddSEQ single-cell sequencing solutions and a broad life-science research portfolio. As a broad incumbent, it competes with Sampling Human across research customers and benefits from established distribution and reagent pull-through.

Emerging players

  • Element Biosciences: Element Biosciences is an emerging sequencing platform company (AVITI) competing with incumbents on cost and flexibility. While not a single-cell pure play, its lower-cost benchtop sequencing instrument could be an enabling or competing technology for Sampling Human-style workflows.
  • Singular Genomics: Singular Genomics develops benchtop sequencers (G4) aimed at flexible, lower-cost sequencing for research and clinical applications. It is an emerging infrastructure competitor whose platform choices affect how customers approach single-cell and cellular-resolution workflows.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Sampling Human social profiles

Digital presence

Sampling Human financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sampling Human leadership team

Management profile

Number of profiles

Profiles6 records

Sampling Human funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sampling Human M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sampling Human

What does Sampling Human do?

Sampling Human builds production systems for generating cellular-resolution data from clinical samples, combining a Sequencing Platform, a Cloud Service, and a physical SamplingOne™ Kit. The platform applies proprietary multidimensional encoding chemistry and AI decoding models to convert clinical samples into standardized, structured cellular data for diagnostics, health products, and AI models. Revenue is generated through platform subscriptions, kit sales, and technical services via direct enterprise sales.

Is Sampling Human a public or private company?

Sampling Human is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sampling Human founded?

Sampling Human was founded in 2022. It employs 11 to 50 people.

Where is Sampling Human based?

Sampling Human is headquartered in Berkeley, United States, in the North America region.

How does Sampling Human make money?

Three revenue lines are on record. Platform Subscription is the primary driver. The others are samplingOne™ Kit Sales and technical Services.

Who are Sampling Human's main competitors?

Direct peers on record are 10x Genomics, Mission Bio, Parse Biosciences, Fluent Biosciences and Akoya Biosciences. Broad incumbents are Becton, Dickinson and Company (BD) — BD Biosciences, Illumina and Bio-Rad Laboratories. Emerging players are Element Biosciences and Singular Genomics.

Does Sampling Human have an API?

No public API is recorded for Sampling Human.

What industry is Sampling Human in?

Sampling Human's product category is Genomics Sequencing Platform. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaSampling Human Raises $2 Million to Support the Development of Engineered Cells for Single Cell AnalysisSampling Human raised $2 million led by i&i Biotech Fund to develop engineered cells for single-cell analysis. The company's platform detects rare cells in millions, aiming to make liquid biopsy faster and cheaper. The funding will advance R&D, hiring, and business development.FinSMEsSampling Human Raises $2M in FundingSampling Human, a San Diego-based life science diagnostics company, raised $2M in funding led by i&i Biotech Fund. The company will use the funds for R&D, hiring, and business development. Its platform, Diagnostics On Target, aims to improve early disease detection.Venture Capital Access OnlineSampling Human Raises $2 Million to Support the Development of Engineered Cells for Single Cell AnalysisSampling Human raised $2 million in funding led by i&i Biotech Fund to support the development of its synthetic biology diagnostic platform. The investment will be used to advance research and development, hiring, and business development for technology that uses engineered cells for single-cell analysis.ZapierSampling Human Raises $2 Million to Support the Development of Engineered Cells for Single Cell AnalysisSampling Human, a life science technology company based in San Diego, has raised $2 million in funding led by i&i Biotech Fund to support the development of its engineered cell diagnostic platform. The investment will be used to advance research and development, hiring, and business development for the company's synthetic biology-based liquid biopsy technology.Business Wire BlogSampling Human Raises $2 Million to Support the Development of Engineered Cells for Single Cell AnalysisSampling Human has raised $2 million in funding led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. The capital will support the R&D and business development of Sampling Human's proprietary platform that uses genetically engineered yeast cells to detect and classify rare living cells for diagnostic purposes.VC News DailySampling Human Raises $2MSampling Human has raised $2 million in funding led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. The San Diego-based company is developing a synthetic biology diagnostic platform that uses genetically engineered cells to detect disease early.